Andrew Zupnick, PhD, Vice President, Oncology Drug Development
In ovarian cancer, multiple factors drive delays. Surgical workflows, biomarker timelines, RECIST complexities, cooperative group oversight, and referral pathways intersect to create these challenges. Below, we identify the main drivers, highlight the key issues that consistently cause avoidable delays, and explain how to mitigate risk.
Ovarian Cancer Isn’t a “Generic Solid Tumor”
Late stage diagnosis is common, disease heterogeneity is the norm, and treatment resistance is frequent. Trial designs taken from other tumor types often fail to account for disease specific realities across frontline, platinum sensitive, platinum resistant, and maintenance populations. This disconnect can lead to flawed eligibility, endpoint, and enrollment criteria.
What to do: Define the exact patient population first. Align eligibility, endpoints, and assessments to that setting; don’t create a generalized template.
Surgical & Pathology Dependencies Change Timelines
Interval debulking, biopsy adequacy, and specimen routing to pathology and labs add days to screening and randomization, especially when a re biopsy is required to confirm eligibility status.
What to do: Premap surgical calendars and tissue workflows, including pathology release requirements, courier logistics, and backup labs. Add realistic screening windows that reflect surgical and pathology turnaround times, then validate with two to three high-throughput gynecologic oncology sites.
Biomarker Reality: BRCA/HRD Access & TATs
Knowledge of BRCA and HRD status is essential, but access and turnaround times vary widely by country and site. Determining CA 125 status also introduces timing dependencies, including the need for response confirmation windows. Each of these factors can quietly extend screening and increase screen failure rates.
What to do: Lock assays, scoring, and backup labs before FPFV milestone. Embed lab-service level agreements, including TAT expectations, into start up documents. Provide CA 125 timing guidance to sites and integrate it directly into visit calendars.
Cooperative Groups Shape Start Up & Budgets
Cooperative groups such as the GOG in the U.S. and ENGOT in the E.U. can accelerate awareness and access to seasoned investigators. But they can also get involved in operational tasks like site selection, contracts, and budgets, which can influence start up speed and prioritization.
What to do: Establish a clear operating cadence among the sponsor, the cooperative group, and the CRO. Align early on-site selection, budget ranges, payment flows, and escalation pathways.
RECIST Interpretation Is Harder in Ovarian Cancer
Common disease features, such as peritoneal studding, ascites, pleural effusions, previously treated lesions, and prior intraperitoneal therapies, make target-lesion selection and response evaluation more challenging in ovarian cancer. Inconsistent interpretation across sites can introduce substantial noise into endpoint assessment and put the primary endpoint of your trial at risk.
What to do: Use central radiology, particularly in later-phase trials. Provide ovarian-specific RECIST training and image acquisition guidance. Align imaging windows with CA125 assessments to reduce discordance.
Referral Patterns Affect Identification
Many patients first present to community OB GYN centers before being referred to gynecologic oncologists. Without an enabled referral pipeline, pre screening opportunities are missed, and valuable time is lost.
What to do: Equip community physicians with plain-language prescreening criteria and a single point of referral. Support borderline cases with rapid prequalification consults and provide ready-to-use patient education sheets to facilitate timely referral.
Global Variability Is Significant & Cannot Be Ignored
Access to biomarker testing, surgical capacity, diagnostic imaging, and the standard of care differ meaningfully by region. Country selection based solely on macro-level disease prevalence often misses site-level throughput and feasibility realities that ultimately determine enrollment performance.
What to do: Combine country-level analytics, such as biomarker testing access and surgical throughput, with historical site-level intake performance. Anchor enrollment with experienced academic centers, supplemented by high-performing regional sites that consistently manage ovarian cancer patients.
Common Questions about Ovarian Cancer Trials: Summarized
Q: Why are ovarian trials slower than expected?
A: Surgical dependencies, biomarker TATs, RECIST nuances, and cooperative group governance add hidden time.
Q: What’s the fastest way to improve feasibility?
A: Lock assays/SLAs early, map tissue workflows, and validate calendars with high-throughput gynecologic sites.
Q: Do I need central radiology?
A: Often yes, in later phases; it standardizes complex ovarian interpretations and reduces endpoint noise.
Let’s Work Together
Don’t let unanticipated roadblocks slow your ovarian cancer program. Connect with Worldwide’s oncology experts to strengthen your trial design — so you can start fast and scale seamlessly.
